ERBB2 and breast carcinoma: Slamon et al. initially demonstrated the association between HER-2 amplification and poor prognosis and related studies following this found that breast cancer patients in Asia-Pacific regions were associated with worse clinical outcomes due to high occurrence of HER-2 amplification [32–34].